• +1-646-491-9876
    • +91-20-67278686

    Search

    Chemotherapy Induced Neutropenia - Pipeline Review, H1 2017

    Chemotherapy Induced Neutropenia - Pipeline Review, H1 2017

    • Report Code ID: RW0001689435
    • Category Healthcare
    • No. of Pages 107
    • Publication Month Mar-17
    • Publisher Name Global Markets Direct
    Report Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Chemotherapy Induced Neutropenia - Pipeline Review, H1 2017, provides an overview of the Chemotherapy Induced Neutropenia (Oncology) pipeline landscape.

    Chemotherapy-induced neutropenia is a very common side effect of cancer treatment. Symptoms include severe fatigue, weakness, anxiety, lack of energy, shortness of breath, headaches, pale appearance, rapid heart rate or palpitations, chest pain dizziness and abdominal pain. The predisposing factors include age, co-morbidities and time course of therapy.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Chemotherapy Induced Neutropenia - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Chemotherapy Induced Neutropenia (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Chemotherapy Induced Neutropenia (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Chemotherapy Induced Neutropenia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 2, 4, 5, 8, 1, 13, 1 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

    Chemotherapy Induced Neutropenia (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Report Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Chemotherapy Induced Neutropenia (Oncology).
    - The pipeline guide reviews pipeline therapeutics for Chemotherapy Induced Neutropenia (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Chemotherapy Induced Neutropenia (Oncology) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Chemotherapy Induced Neutropenia (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Chemotherapy Induced Neutropenia (Oncology)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Chemotherapy Induced Neutropenia (Oncology).
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Chemotherapy Induced Neutropenia (Oncology) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Chemotherapy Induced Neutropenia - Overview
    Chemotherapy Induced Neutropenia - Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Pipeline by Universities/Institutes
    Products under Development by Companies
    Products under Development by Universities/Institutes
    Chemotherapy Induced Neutropenia - Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Chemotherapy Induced Neutropenia - Companies Involved in Therapeutics Development
    Apotex Inc
    Biocon Ltd
    Biogenomics Ltd
    Bolder Biotechnology Inc
    Cellerant Therapeutics Inc
    Chong Kun Dang Pharmaceutical Corp
    Cinfa Biotech SL
    Dr. Reddy's Laboratories Ltd
    Gene Techno Science Co Ltd
    Generon (Shanghai) Corp Ltd
    Genexine Inc
    GlycoMimetics Inc
    Hanmi Pharmaceuticals Co Ltd
    Mycenax Biotech Inc
    Myelo Therapeutics GmbH
    Nohla Therapeutics Inc
    Octapharma AG
    Pfenex Inc
    Pfizer Inc
    Reliance Life Sciences Pvt Ltd
    Richter Gedeon Nyrt
    Sandoz International GmbH
    USV Pvt Ltd
    Chemotherapy Induced Neutropenia - Drug Profiles
    BBT-007 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    BBT-015 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    BBT-018 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Cell Therapy for Chemotherapy Induced Neutropenia - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Cell Therapy for Chemotherapy Induced Neutropenia - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    EC-18 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    eflapegrastim - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    F-627 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    filgrastim - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    filgrastim - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    filgrastim - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    filgrastim - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    filgrastim - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    filgrastim - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    filgrastim - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    GMI-1271 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    GW-003 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    GXG-3 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    HSA-GCSF - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Myelo-001 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    pegfilgrastim - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    pegfilgrastim - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    pegfilgrastim - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    pegfilgrastim - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    pegfilgrastim - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    pegfilgrastim - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    pegfilgrastim - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    pegfilgrastim - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    pegfilgrastim - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    pegfilgrastim - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    pegfilgrastim - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    pegfilgrastim - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    pegfilgrastim - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    pegfilgrastim - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    pegfilgrastim - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    romyelocel-L - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    TXA-302 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    WBI-2100 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    YPEG-Filgrastim - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Chemotherapy Induced Neutropenia - Dormant Projects
    Chemotherapy Induced Neutropenia - Discontinued Products
    Chemotherapy Induced Neutropenia - Product Development Milestones
    Featured News & Press Releases
    Feb 16, 2017: U.S. FDA Accepts Biologics License Application for Mylan and Biocon's Proposed Biosimilar Pegfilgrastim for Review
    Dec 05, 2016: Spectrum Pharmaceuticals Highlights Four Abstracts on ROLONTIS (eflapegrastim) at the San Antonio Breast Cancer Symposium (SABCS) in San Antonio, Texas, December 6-10, 2016
    Dec 02, 2016: Cinfa Biotech publishes clinical data abstract at the 58th American Society of Hematology Annual Meeting 2016
    Sep 26, 2016: Cinfa Biotech starts second clinical study of pegfilgrastim biosimilar candidate B12019
    Jul 04, 2016: Cinfa Biotech announces positive top-line clinical data of pegfilgrastim biosimilar candidate B12019
    Dec 16, 2015: Spectrum Pharmaceuticals Announces Agreement with FDA on the Special Protocol Assessment for the Registrational Trial of SPI-2012, a Novel, Long Acting G-CSF in Patients with Breast Cancer
    Dec 08, 2014: Generon Presents the Global Phase II Study Results for F-627 (benegrastim) at the American Society of Hematology 56th Annual Meeting at San Francisco
    Sep 09, 2014: Spectrum Pharmaceuticals Makes Decision to Advance SPI-2012, a Novel Long-Acting GCSF, to Phase 3 Due to Positive Phase 2 Results in its Collaboration Program with Hanmi Pharm
    May 28, 2014: Spectrum Pharmaceuticals Completes Enrollment in Phase 2 Trial of SPI-2012 - A Novel Long-Acting Granulocyte Colony Stimulating Factor to Treat Chemotherapy-induced Neutropenia
    Apr 08, 2013: Spectrum Pharma Initiates Phase II Study Of Long-acting GCSF Drug Candidate SPI-2012 For Treatment Of Chemotherapy-induced Neutropenia
    Jan 07, 2013: Generon Initiates Phase I/II Clinical Trial Of F-627 For Treatment Of Breast Cancer In China
    May 10, 2011: Dr Reddy’s Launches Pegfilgrastim In India Under Brand Name Peg-grafeel
    Mar 22, 2011: Cellerant Initiates Phase I/II Clinical Trial Of CLT-008 For Chemotherapy Induced Neutropenia In Acute Leukemia Patients
    Dec 08, 2010: Generon Presents Poster On F-627 At 52nd Annual Meeting Of American Society Of Hematology
    Nov 22, 2010: Generon Completes Dosing In Phase I Study Of F-627 In Australia
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Chemotherapy Induced Neutropenia, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017 (Contd..1), H1 2017
    Products under Development by Companies, H1 2017 (Contd..2), H1 2017
    Products under Development by Universities/Institutes, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Chemotherapy Induced Neutropenia - Pipeline by Apotex Inc, H1 2017
    Chemotherapy Induced Neutropenia - Pipeline by Biocon Ltd, H1 2017
    Chemotherapy Induced Neutropenia - Pipeline by Biogenomics Ltd, H1 2017
    Chemotherapy Induced Neutropenia - Pipeline by Bolder Biotechnology Inc, H1 2017
    Chemotherapy Induced Neutropenia - Pipeline by Cellerant Therapeutics Inc, H1 2017
    Chemotherapy Induced Neutropenia - Pipeline by Chong Kun Dang Pharmaceutical Corp, H1 2017
    Chemotherapy Induced Neutropenia - Pipeline by Cinfa Biotech SL, H1 2017
    Chemotherapy Induced Neutropenia - Pipeline by Dr. Reddy's Laboratories Ltd, H1 2017
    Chemotherapy Induced Neutropenia - Pipeline by Gene Techno Science Co Ltd, H1 2017
    Chemotherapy Induced Neutropenia - Pipeline by Generon (Shanghai) Corp Ltd, H1 2017
    Chemotherapy Induced Neutropenia - Pipeline by Genexine Inc, H1 2017
    Chemotherapy Induced Neutropenia - Pipeline by GlycoMimetics Inc, H1 2017
    Chemotherapy Induced Neutropenia - Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2017
    Chemotherapy Induced Neutropenia - Pipeline by Mycenax Biotech Inc, H1 2017
    Chemotherapy Induced Neutropenia - Pipeline by Myelo Therapeutics GmbH, H1 2017
    Chemotherapy Induced Neutropenia - Pipeline by Nohla Therapeutics Inc, H1 2017
    Chemotherapy Induced Neutropenia - Pipeline by Octapharma AG, H1 2017
    Chemotherapy Induced Neutropenia - Pipeline by Pfenex Inc, H1 2017
    Chemotherapy Induced Neutropenia - Pipeline by Pfizer Inc, H1 2017
    Chemotherapy Induced Neutropenia - Pipeline by Reliance Life Sciences Pvt Ltd, H1 2017
    Chemotherapy Induced Neutropenia - Pipeline by Richter Gedeon Nyrt, H1 2017
    Chemotherapy Induced Neutropenia - Pipeline by Sandoz International GmbH, H1 2017
    Chemotherapy Induced Neutropenia - Pipeline by USV Pvt Ltd, H1 2017
    Chemotherapy Induced Neutropenia - Dormant Projects, H1 2017
    Chemotherapy Induced Neutropenia - Dormant Projects, H1 2017 (Contd..1), H1 2017
    Chemotherapy Induced Neutropenia - Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development for Chemotherapy Induced Neutropenia, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products by Targets, H1 2017
    Number of Products by Stage and Targets, H1 2017
    Number of Products by Mechanism of Actions, H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    Apotex Inc
    Biocon Ltd
    Biogenomics Ltd
    Bolder Biotechnology Inc
    Cellerant Therapeutics Inc
    Chong Kun Dang Pharmaceutical Corp
    Cinfa Biotech SL
    Dr. Reddy's Laboratories Ltd
    Gene Techno Science Co Ltd
    Generon (Shanghai) Corp Ltd
    Genexine Inc
    GlycoMimetics Inc
    Hanmi Pharmaceuticals Co Ltd
    Mycenax Biotech Inc
    Myelo Therapeutics GmbH
    Nohla Therapeutics Inc
    Octapharma AG
    Pfenex Inc
    Pfizer Inc
    Reliance Life Sciences Pvt Ltd
    Richter Gedeon Nyrt
    Sandoz International GmbH
    USV Pvt Ltd

    Request for Sample

    Report Url http://www.reportsweb.com//chemotherapy-induced-neutropenia-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//chemotherapy-induced-neutropenia-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//chemotherapy-induced-neutropenia-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments